NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.

LAMA2 Muscular Dystrophy

Synonym: Laminin α2 Chain-Deficiency
, MSc, PhD
Center for Predictive and Preventive Genetics and UnIGENe
Institute for Molecular and Cell Biology
i3S – Instituto de Investigação e Inovação em Saúde
Universidade do Porto
Porto, Portugal
, MD
Center for Predictive and Preventive Genetics and UnIGENe
Institute for Molecular and Cell Biology
i3S – Instituto de Investigação e Inovação em Saúde
Universidade do Porto
Porto, Portugal
, MD
Unidade de Doenças Neuromusculares e Unidade de Neuropediatria
Centro Materno-Infantil Albino Aroso
Centro Hospitalar Universitário do Porto
Porto, Portugal
, MD, PhD
Unidade Neuromusculares e Serviço de Neurofisiologia
Centro Hospitalar Universitário do Porto
Porto, Portugal

Initial Posting: ; Last Update: September 17, 2020.

Estimated reading time: 33 minutes

Summary

Clinical characteristics.

The clinical manifestations of LAMA2 muscular dystrophy (LAMA2-MD) comprise a continuous spectrum ranging from severe congenital muscular dystrophy type 1A (MDC1A) to milder late-onset LAMA2-MD. MDC1A is typically characterized by neonatal profound hypotonia, poor spontaneous movements, and respiratory failure. Failure to thrive, gastroesophageal reflux, aspiration, and recurrent chest infections necessitating frequent hospitalizations are common. As disease progresses, facial muscle weakness, temporomandibular joint contractures, and macroglossia may further impair feeding and can affect speech.

In late-onset LAMA2-MD onset of manifestations range from early childhood to adulthood. Affected individuals may show muscle hypertrophy and develop a rigid spine syndrome with joint contractures, usually most prominent in the elbows. Progressive respiratory insufficiency, scoliosis, and cardiomyopathy can occur.

Diagnosis/testing.

The diagnosis of LAMA2 muscular dystrophy is established in a proband with suggestive findings and biallelic (homozygous or compound heterozygous) pathogenic variants in LAMA2 identified by molecular genetic testing.

Management.

Treatment of manifestations: It is recommended that multidisciplinary care be provided by specialists in neurology, gastroenterology, nutrition, orthopedics, occupational and physical therapy, speech and language therapy, education, psychiatry, pulmonary medicine, cardiology, ophthalmology, and social work.

Surveillance: Routine follow up of nutritional status and safety of oral intake, neurologic status, pulmonary function, developmental/educational progress, cognitive abilities, psychiatric issues, mobility and activities of daily living, cardiac status, vision, and social needs.

Agents/circumstances to avoid: Succinylcholine in induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities; statins, cholesterol-lowering medications, because of the risk of muscle damage.

Genetic counseling.

LAMA2-MD is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a LAMA2 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the LAMA2 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal and preimplantation genetic testing are possible.

GeneReview Scope

LAMA2 Muscular Dystrophy: Included Phenotypes
  • Congenital muscular dystrophy type 1A (MDC1A)
  • Late-onset LAMA2 muscular dystrophy

For synonyms and outdated names see Nomenclature.

Diagnosis

The phenotypic spectrum of LAMA2 muscular dystrophy (LAMA2-MD) ranges from congenital muscular dystrophy type 1A (MDC1A) to LAMA2-MD with onset ranging from early childhood to adulthood (referred to as late-onset LAMA2-MD).

No consensus clinical diagnostic criteria for LAMA2-MD have been published.

Suggestive Findings

LAMA2-muscular dystrophy should be suspected in individuals with the following clinical findings by age of onset; laboratory and neuroimaging findings regardless of age; and family history.

Clinical Findings by Age of Onset

Congenital muscular dystrophy type 1A (MDC1A)

  • Onset at birth or within the first six months of life: profound hypotonia with muscle weakness
  • Poor spontaneous movements with contractures of the large joints
  • Feeding difficulties with failure to thrive, aspiration, and recurrent chest infections
  • Delayed motor development milestones: the majority of affected individuals are able to sit but rarely achieve independent ambulation.
  • Axial weakness, difficulties in head control (mainly due to flexor muscles of the neck); progressive scoliosis starting in childhood
  • Absence of findings that could suggest lower motor neuron disease (i.e., tongue fasciculation and areflexia)
  • Usually normal intellect
  • Less common findings:
    • Weak cry often associated with respiratory failure
    • Epilepsy, including of a refractory nature
    • Cardiac involvement
    • Demyelinating progressive sensorimotor neuropathy

Late-onset LAMA2-MD (clinically heterogeneous group)

  • Onset during childhood or even adulthood
  • Proximal muscle weakness with or without muscle hypertrophy, as seen in limb-girdle muscular dystrophies
  • Delayed motor milestones in childhood, but independent ambulation usually achieved
  • Less common findings:
    • Rigid spine syndrome with joint contractures usually most prominent in the elbows
    • Childhood-onset seizures
    • Progressive respiratory insufficiency and scoliosis
    • Cardiomyopathy with or without conduction defect

Laboratory and Neuroimaging Findings

Serum creatine kinase (CK) concentration

  • MDC1A. In the first years of life, serum CK concentration may be more than fourfold normal values [Hayashi et al 2001, Oliveira et al 2008]. In children with MDC1A who do not achieve walking, serum CK concentration is usually more than 1000 IU/L in the first two years of life, after which it progressively decreases.
  • Late-onset LAMA2-MD. Maximum serum CK concentrations range from 593 IU/L to 6987 IU/L (normal 200-400 depending on laboratory) [Oliveira et al 2008]. In adults, CK levels could be only mildly or slightly elevated [Rajakulendran et al 2011, Oliveira et al 2018].

Brain MRI findings (regardless of age)

  • Abnormal white matter signals (in nearly all individuals with LAMA2-MD) include hyperintensity on T2-weighted and FLAIR MRI, and hypointensity on T1-weighted images in areas myelinated in the developing brain (i.e., subcortical and periventricular areas) with sparing of areas myelinated later in life (i.e., corpus callosum and internal capsule) [Geranmayeh et al 2010]. These findings, consistently documented in the first year of life, do not represent areas of demyelination but rather are likely secondary to leaky basal laminar connections giving rise to increased water content in the brain [Menezes et al 2014]. Although these white matter changes are mostly diffuse, focal and more subtle changes are seen in a small subset of affected individuals [Leite et al 2005, Chan et al 2014, Oliveira et al 2018]. Of note, two sibs with a late-onset phenotype were reported to have a nearly normal brain MRI [Saredi et al 2019].
  • Structural brain abnormalities (secondary to neuronal migration defects) include cortical dysplasia [Mercuri et al 1999], lissencephaly (agyria or pachygyria) [Geranmayeh et al 2010], and polymicrogyria [Vigliano et al 2009].
    Polymicrogyria-like patterns (bilaterally in the temporal and occipital lobes) were reported in the majority of 25 individuals. When extensive, the polymicrogyria correlated with epilepsy [Natera-de Benito et al 2020].

Immunohistochemistry (IHC) of muscle or skin biopsy

  • Complete or partial laminin α2 deficiency (muscle and skin)
  • Increased expression of laminin α4 and α5

Muscle MRI findings. Muscle imaging, including whole-body MRI, is being increasingly used in the diagnostic workup of hereditary myopathies. Although the appearance of muscle on MRI in LAMA2-MD is similar to that of the collagen VI myopathies (see Differential Diagnosis), with bands of sparing and affected muscles [Nelson et al 2015, Harris et al 2017], the anterior thigh muscles are more frequently involved in LAMA2-MD. Sparing of the gracilis, sartorius, vastus medialis, and rectus femoris muscles has also been described [Nelson et al 2015]. Individuals with rigid spine syndrome had sparing of temporal muscles, except in those associated with biallelic LAMA2 pathogenic variants [Tordjman et al 2018].

Family History

Family history is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis.

Establishing the Diagnosis

The diagnosis of LAMA2 muscular dystrophy is established in a proband with suggestive findings and biallelic (homozygous or compound heterozygous) pathogenic (or likely pathogenic) variants in LAMA2 identified by molecular genetic testing (see Table 1).

Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) Identification of biallelic LAMA2 variants of uncertain significance (or identification of one known LAMA2 pathogenic variant and one LAMA2 variant of uncertain significance) does not establish or rule out the diagnosis.

Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing, a variety of multigene panels) and comprehensive genomic testing (exome sequencing, exome array, chromosomal microarray (CMA), genome sequencing) depending on the phenotype.

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas comprehensive genomic testing does not. Individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those with later onset or with an atypical phenotype, in whom the diagnosis of LAMA2-muscular dystrophy has not been considered, are more likely to be diagnosed using a larger multigene panel (Option 2) or even comprehensive genomic testing (see Option 3).

Option 1

When the phenotypic and laboratory findings suggest the diagnosis of LAMA2-MD, molecular genetic testing approaches can include single-gene testing. Sequence analysis of LAMA2 detects small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. Perform sequence analysis first. If only one or no pathogenic variant is found perform gene-targeted deletion/duplication analysis (e.g. multiplex-ligation dependent probe amplification or CMA) to detect intragenic large deletions or duplications that may be missed by Sanger sequencing.

Option 2

A muscular dystrophy multigene panel that includes LAMA2 and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Option 3

When the diagnosis of LAMA2-MD is not considered because an individual has atypical phenotypic findings, comprehensive genomic testing, which does not require the clinician to determine which gene is likely involved, is most likely to lead to diagnosis. Exome sequencing is most commonly used [Oliveira et al 2018, Saredi et al 2019]; genome sequencing may also be considered if clinically available.

If exome sequencing is not diagnostic, exome array (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Table 1.

Molecular Genetic Testing Used in LAMA2 Muscular Dystrophy

Gene 1MethodProportion of Pathogenic Variants 2 Detectable by Method
LAMA2 Sequence analysis 3~80% 4
Gene-targeted deletion/duplication analysis 5~20% 6
1.

See Table A. Genes and Databases for chromosome locus and protein.

2.

See Molecular Genetics for information on variants detected in this gene.

3.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

4.
5.

Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

6.

Clinical Characteristics

Clinical Description

The clinical manifestations of LAMA2 muscular dystrophy (LAMA2-MD) comprise a continuous spectrum ranging from severe congenital muscular dystrophy type 1A (MDC1A) to milder late-onset LAMA2-MD.

Those with congenital muscular dystrophy type 1A (MDC1A) typically have neonatal profound hypotonia, poor spontaneous movements, and respiratory failure [Jones et al 2001]. Failure to thrive, gastroesophageal reflux, aspiration, and recurrent chest infections necessitating frequent hospitalizations are common. As disease progresses, facial muscle weakness, temporomandibular joint contractures, and macroglossia may further impair feeding and can affect speech.

Late-onset LAMA2-MD is characterized by later onset of manifestations, ranging from early childhood to adulthood. Affected individuals may show muscle hypertrophy and develop a rigid spine syndrome with joint contractures, usually most prominent in the elbows. Progressive respiratory insufficiency and scoliosis can occur [He et al 2001] along with cardiomyopathy [Carboni et al 2011, Marques et al 2014].

Congenital Muscular Dystrophy Type 1A (MDC1A)

Respiratory involvement is caused by a progressively restrictive chest wall that first involves weakness of the intercostal and accessory muscles. Early in childhood, the thorax becomes stiff and chest wall compliance decreases, further contributing to alveolar hypoventilation, atelectasis, and mucous plugs with bronchial obstruction. These changes manifest as low lung volumes. Poor secretion clearance resulting from weak cough leads to recurrent chest infection. Swallowing difficulties and gastroesophageal reflux may increase the risk of aspiration. Chest infections may cause atelectasis, which along with limited pulmonary reserve, increases the risk of acute respiratory failure in the setting of infection.

The need for ventilatory support is most likely to occur during two time periods [Geranmayeh et al 2010]:

  • Between birth and age five years in the most severely affected children mainly due to respiratory muscle weakness, hypotonia, and fatigue. Depending on age, total hours of ventilatory support required, frequency of hospitalizations, and institutional practice patterns, ventilatory support may be noninvasive or mechanical with tracheostomy. Respiratory issues in these infants and young children often stabilize in the first years, likely as a result of improved muscle tone.
  • Between ages ten and 15 years due to progressive restrictive lung disease leading to respiratory insufficiency [Wallgren-Pettersson et al 2004]. Most children in this age group with the early-onset form do not have typical signs/symptoms of hypercapnia (i.e., headaches, attention difficulties, and drowsiness) but rather the more subtle findings including recurrent respiratory infections, failure to thrive, poor cough, and fatigue with feeding.

Feeding difficulties, consistent with poor weight gain, failure to thrive, and precipitous drop in weight with infections and hospitalizations are common. Philpot et al [1999a] reported weight below the third centile and feeding difficulties including swallowing abnormalities, difficulty chewing, and prolonged feeding time. In a study of 46 individuals with LAMA2-MD, 17 required enteral feeding, usually within the first year [Geranmayeh et al 2010]. Of note, children with early-onset LAMA2-MD do not attain normal weight (see Management, Treatment of Manifestations).

Joint contractures that are present in the first year of life progress slowly even in children receiving intensive daily physical therapy. Contractures tend to occur early in the shoulders, elbows, hips, and knees and later in the temporomandibular joints, distal joints, and cervical spine. Contractures often result in significant morbidity and interfere with activities of daily living.

Hyperlaxity of the distal phalanges of the fingers is observed in a number of affected children.

Motor developmental milestones are delayed and often arrested. Most affected children do not acquire independent walking; Geranmayeh et al [2010] reported that only 15% of individuals acquired independent ambulation. A smaller proportion gained the ability to walk with assistance but subsequently lost the ability.

Axial weakness

  • Neck weakness, especially of the flexor muscles, impairs moving the head from the back to neutral position or performing neck flexion and lifting head from the lying position [Oliveira et al 2018]. This weakness may progress to a severe cervical lordosis in late adolescence, affecting the capacity to swallow and increasing the risk of food aspiration.
  • Scoliosis is aggravated by thoracic and lumbar lordosis and frequently observed from the first decade of life [Bentley et al 2001]. It is often slowly progressive and may contribute to respiratory insufficiency due to thoracic restriction and airway compression.

Facial muscle weakness and macroglossia may become significant in toddlers and children, resulting in typical elongated myopathic facies, with an open mouth and tongue protrusion.

Limitation of eye movements (ophthalmoparesis) may be evident as early as age two years.

Central nervous system. Cognitive abilities are normal in the majority of affected individuals and do not correlate with brain MRI abnormalities [Messina et al 2010]; however, in a small proportion of individuals, intellectual disability and epilepsy were associated with bilateral occipital pachygyria [Jones et al 2001] or dysplastic cortical changes affecting predominantly the occipital and temporal regions [Sunada et al 1995, Pini et al 1996, Philpot et al 1999b, Leite et al 2005, Geranmayeh et al 2010, Natera-de Benito et al 2020].

Cognitive impairment, reported in fewer than 7% of individuals [Jones et al 2001, Geranmayeh et al 2010], ranged from mild intellectual disability to communication difficulties.

Epilepsy occurs in 8%-35% of affected individuals. Epilepsy is more prevalent in persons with more extensive cortical malformation. Seizures are mainly focal and visual aura; autonomic signs are common. Atypical absence, atonic, motor, and focal seizures with clonic bilateralization can also occur. In some individuals epilepsy is controlled with mono- or polytherapy, whereas in others epilepsy can be refractory, leading to a progressive deterioration of cognition [Vigliano et al 2009, Geranmayeh et al 2010, Natera-de Benito et al 2020].

A progressive sensorimotor neuropathy with signs of dysmyelinization may be detected in childhood [Di Muzio et al 2003]. These abnormalities are usually mild or clinically not significant. In contrast, needle EMG, even when performed early in infancy, shows myopathic signs in a majority of individuals [Quijano-Roy et al 2004].

Cardiac involvement has been described in persons with late-onset LAMA2-MD. There are only a few reports of cardiac involvement in individuals with MDC1A [Abdel Aleem et al 2020]; however, as improved medical care prolongs life expectancy, cardiac involvement may become more prevalent, and thus a management concern [Nelson et al 2015].

Secondary pulmonary hypertension may be observed as a complication of respiratory insufficiency [Geranmayeh et al 2010].

Late-Onset LAMA2 Muscular Dystrophy

The onset of this milder phenotype ranges from early childhood to adulthood. Although children may have delayed motor milestones, they acquire independent ambulation. Proximal muscle weakness is slowly progressive in a pattern similar to that of other limb-girdle muscular dystrophies. Long-term consequences include wheelchair dependence, scoliosis, and respiratory problems [Oliveira et al 2018].

Weakness is also associated with marked contractures (mainly in the elbows and Achilles tendon) [Harris et al 2017, Saredi et al 2019] and heart involvement that can be clinically significant (particularly in individuals with phenotypes resembling Emery-Dreifuss muscular dystrophy or collagen VI diseases); however, subclinical abnormal echocardiograms and/or EKG-Holter findings are more common [Nelson et al 2015, Harris et al 2017].

Some individuals have rigid spine syndrome and/or muscle pseudohypertrophy [Nelson et al 2015].

Peripheral nerve demyelination may be detected with nerve conduction studies; however, most commonly there are no significant clinical consequences [Chan et al 2014].

Severe epilepsy and intellectual disability are described in some individuals.

Genotype-Phenotype Correlations

Prognostication of clinical severity depends on several variables including age at onset of first manifestations, LAMA2 pathogenic variant type, and, if known, the effect of the variant on protein function [Geranmayeh et al 2010, Oliveira et al 2018]. See Table 6 for the phenotypes associated with several commonly reported pathogenic variants.

Complete absence of laminin α2 and the phenotype of congenital muscular dystrophy type 1A (MDC1A) in general are caused by loss-of-function LAMA2 variants [Pegoraro et al 1998, Oliveira et al 2008, Oliveira et al 2018]; however, exceptions occur, including an individual homozygous for a pathogenic nonsense LAMA2 variant who achieved ambulation [Geranmayeh et al 2010]. Intrafamilial variation has also been observed [Geranmayeh et al 2010, Oliveira et al 2018].

Partial deficiency of laminin α2. The phenotypes associated with partial deficiency of laminin α2 tend to be less severe, with slower disease progression [Allamand & Guicheney 2002, Tezak et al 2003, Oliveira et al 2018]. Some missense, splice site, and in-frame variants have been associated with partial deficiency as well as pathogenic missense variants in conserved cysteine residues on the short arm of the laminin α2 protein [Allamand & Guicheney 2002, Tezak et al 2003, Oliveira et al 2018]. Late-onset LAMA2-MD has been observed in multiple individuals with the variant c.2461A>C (p.Thr821Pro) in homozygosity or compound heterozygosity with another variant [Oliveira et al 2018].

Nomenclature

Individuals with early-onset LAMA2-MD were often categorized in the past as having complete or partial laminin α2 deficiency (or complete or partial merosin deficiency before it was known that the defect was laminin α2 deficiency) based on immunochemistry (IHC) staining of muscle. These IHC-based terms are less relevant now, given that the diagnosis of LAMA2 muscular dystrophy can be made with certainty by the detection of biallelic LAMA2 pathogenic variants. Moreover, laminin α2 deficiency can be secondary to defects in other proteins involved in the dystroglycan complex or pathway (e.g., in dystroglycanopathies; see Differential Diagnosis) [Bönnemann et al 2014, Endo 2015].

The abbreviation MDC1A is derived from the designation merosin-deficient congenital muscular dystrophy type 1A.

Based on a nomenclature system that describes which chains are present in each laminin isoform, merosin was given the name laminin-211 because it comprises chains α2, β1, and γ1.

Late-onset LAMA2 muscular dystrophy may also be referred to as LGMDR23 [Straub et al 2018].

Prevalence

Exact prevalence of congenital muscular dystrophy type 1A (MDC1A) is still unknown. The prevalence of congenital muscular dystrophies (CMD) has been estimated between 0.563:100,000 (in Italy [Graziano et al 2015]) and 2.5:100,000 (in western Sweden [Darin & Tulinius 2000]).

Geographic prevalence of MDC1A is also quite variable:

  • In Europe it accounts for about 30% of CMD, whereas in Japan it accounts for only 6% [Allamand & Guicheney 2002].
  • In the United Kingdom it accounts for 37.4% of CMD, making it the most common cause [Sframeli et al 2017].
  • In Italy it accounts for 24.1% of CMD, making it the second most common cause [Graziano et al 2015].
  • In Australia it accounts for 16% of CMD, making it the third most common cause [O'Grady et al 2016].

Differential Diagnosis

Congenital muscular dystrophy type 1A (MDC1A) must be distinguished from other disorders that may present with profound hypotonia (with frog leg posture of the legs), chest deformity, and breathing and feeding problems. The disorders included in the differential diagnosis are other congenital muscular dystrophies, congenital myopathies, congenital myasthenic syndromes, and spinal muscular atrophy. Of note, these disorders are not typically associated with: (1) laminin-α2 deficiency detected by immunohistochemical staining of muscle or skin biopsy, or (2) white matter changes on brain MRI. Additional distinguishing features include:

  • Progressive improvement of tone and strength (in some affected individuals), CK levels near normal range values, diagnostic structural abnormalities on muscle biopsy (by light and electron microscopy), and an absence of joint contractures (even when the disease is severe) in the congenital myopathies;
  • Multisystemic presentation (e.g., liver and cardiac involvement besides muscle weakness) in congenital metabolic myopathies.

Table 2a.

Selected Genes of Interest in the Differential Diagnosis of MDC1A

Gene(s)DisorderMOIDistinguishing Clinical Features 1
B3GALNT2
B4GAT1
CRPPA
DAG1
FKRP
FKTN
GMPPB
LARGE1
POMGNT1
POMGNT2
POMK
POMT1
POMT2
RXYLT1 		Dystroglycanopathies, congenital (OMIM PS236670)ARWide variety of brain & eye structural & functional abnormalities (may be more severe in Walker Warburg syndrome & muscle-eye-brain disease)
COL6A1
COL6A2
COL6A3 		Collagen type VI disorders (Ullrich CMD) 2AR 3Characterized by triad of myopathic features, hyperlaxity, & typical skin changes (keratosis pilaris, keloids, striae)
BIN1
CCDC78
DNM2
MAP3K20
MTM1
MTMR14
SPEG 		Centronuclear/myotubular myopathy 4 (See X-Linked Myotubular Myopathy.)XL
AR
AD		Ophthalmoplegia; facial bulbar weakness
ACTA1
CFL2
KBTBD13
KLHL40
KLHL41
LMOD3
NEB
TNNT1
TPM2
TPM3 		Nemaline myopathy 4 (OMIM PS161800)AR
AD		Facial & bulbar weakness
RYR1 Central core disease (OMIM 117000) &
multiminicore disease (OMIM 255320) 4		AR
AD 5		Malignant hyperthermia in some affected individuals
SELENON Congenital myopathy w/fiber-type disproportionAD
AR		Insulin resistance
Rigid spine (congenital) muscular dystrophy (OMIM 602771)ARRestrictive respiratory syndrome (nocturnal hypoventilation)
CHAT
CHRNE
COLQ
DOK7
GFPT1
RAPSN 6		 Congenital myasthenic syndromes AR
AD		Facial & bulbar weakness; striking motor variability; decremental EMG response or abnormal single-fiber EMG
SMN1 7 Spinal muscular atrophy ARRelatively rapid motor impairment & tongue fasciculations; EMG & muscle biopsy findings suggest denervation-reinnervation profile; normal nerve conduction studies

AD = autosomal dominant; AR = autosomal recessive; CMD = congenital muscular dystrophy; MOI = mode of inheritance; XL = X-linked

1.

In addition to absence of brain white matter changes

2.

Immunohistochemical analysis of muscle or skin biopsies can be diagnostically useful, showing variable reduction of antibody labeling against collagen VI or glycosylated α-dystroglycan.

3.

The Ullrich congenital muscular dystrophy phenotype is usually inherited in an autosomal recessive manner; however, exceptions occur.

4.

Selected examples of congenital myopathies are included in Table 2a; other congenital myopathies may also be relevant to the differential diagnosis of MDC1A.

5.

Minicore disease is most often inherited in an autosomal recessive manner. The report of minicore disease in two generations in a few families also suggested autosomal dominant inheritance.

6.

Most commonly associated of ~30 known genes; pathogenic variants in one of multiple genes encoding proteins expressed at the neuromuscular junction are currently known to be associated with subtypes of congenital myasthenic syndromes.

7.

The detection of the genetic defect causing spinal muscular atrophy (deletion involving SMN1 exons 7 and 8) requires specific methodologies.

Late-onset LAMA2 muscular dystrophy (LAMA2-MD) is in the differential diagnosis of childhood-onset weakness of the limb-girdle type.

Table 2b.

Genes of Interest in the Differential Diagnosis of Late-Onset LAMA2-MD

GenesDifferential DisorderMOIClinical Features of the Differential Disorder
Overlapping w/LAMA2-MDDistinguishing from LAMA2-MD
EMD
FHL1
LMNA 		Emery-Dreifuss muscular dystrophy 1XL
AR
AD		Elbow contractures, high serum CK concentrations, prominent spinal rigidity
  • Cardiac disease (in all affected persons) w/conduction defects & arrhythmias
  • Absence of the characteristic brain MRI findings assoc w/LAMA2-MD
COL6A1
COL6A2
COL6A3 		Collagen type VI disorders (Bethlem myopathy) 2AR
AD		Elbow or Achilles tendon contractures; mildly ↑ serum CK concentrations
  • Contractures, present early in disease, can be more disabling than muscle weakness & usually → persistent severe flexion contractures.
  • If no typical skin changes (e.g., keloids), differential diagnosis is difficult.
  • Suggestive findings on muscle MRI

AD = autosomal dominant; AR = autosomal recessive; MOI = mode of inheritance; XL = X-linked

1.

Immunofluorescence and/or western blot in fresh muscle biopsies (or from other affected tissues) can be used to detect changes in emerin or FHL1 proteins.

2.

Immunohistochemical (IHC) analysis of muscle or skin biopsies can be diagnostically useful, showing variable reduction of antibody labeling against collagen VI.

Management

Published consensus clinical practice guidelines for congenital muscular dystrophies list recommendations for the following six clinical care areas: neurology, pulmonary, gastrointestinal/nutritional/oral care, orthopedics and rehabilitation, cardiology, and palliative care [Wang et al 2010] (full text).

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs of a child diagnosed with LAMA2 muscular dystrophy (LAMA2-MD), the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Table 3.

Recommended Evaluations Following Initial Diagnosis in Individuals with LAMA2 Muscular Dystrophy

System/ConcernEvaluationComment
Constitutional Height, weight, & nutritional status
Neurologic Complete exam by experienced neurologistTo incl assessment of strength
For seizures or unexplained fainting or loss of consciousnessTo incl EEG
Musculoskeletal Multidisciplinary neuromuscular clinic assessment by orthopedist, physical medicine, OT/PTTo incl assessment of:
  • Gross motor & fine motor skills
  • Contractures, clubfoot, & kyphoscoliosis
  • Need for adaptive devices
  • Need for PT (for improving gross motor skills) &/or OT (for improving fine motor skills)
Feeding Gastroenterology / nutrition / feeding teamAssessment of:
  • Nutritional status
  • For GERD
  • Constipation
  • Secretion management, aspiration risk
  • Optimal position for feeding
  • Bone health (serum concentrations of vitamin D & calcium)
Oral health Dental examBefore age 2 yrs (or at diagnosis) w/attention to enamel defects secondary to GERD, dry mouth, malocclusion/dental crowding interfering w/daily dental care
Respiratory By pulmonologist
  • Assess pulmonary function.
  • Evaluate for evidence of nocturnal hypoventilation esp in children w/recurrent respiratory infections, FTT, poor cry, or feeding fatigue.
Neurodevelopmental Developmental assessment
  • To incl motor, speech/language eval, & general cognitive skills
  • Eval for early intervention/special education in least restrictive educational environment
Cognitive/
Psychiatric 		As determined by developmental pediatrician / mental health consultantTo determine if there are concerns about learning or mood, behavior, or other psychiatric issues
Cardiac By cardiologistFor evidence of cardiomyopathy &/or arrhythmia
Ophthalmologic By ophthalmologistFor evidence of ophthalmoparesis
Genetic counseling By genetics professionals 1To inform affected persons & their families re nature, MOI, & implications of LAMA2-MD to facilitate medical & personal decision making
Family/Community Assess:
  • Social work involvement to connect families w/local resources, respite, & support;
  • Care coordination to manage multiple subspecialty appointments, equipment, medications, & supplies;
  • Need for palliative care.

FTT = failure to thrive; GERD = gastroesophageal reflux disease; MOI = mode of inheritance; OT = occupational therapist/therapy; PT = physical therapist/therapy

1.

Medical geneticist, certified genetic counselor, or certified advanced genetic nurse

Treatment of Manifestations

Management ideally involves multidisciplinary care by specialists in relevant fields (see Table 4).

Table 4.

Treatment of Manifestations in Individuals with Congenital Muscular Dystrophy Type 1A

Manifestation/ConcernTreatmentConsiderations/Other
DD/ID See Developmental Delay / Intellectual Disability Management Issues.
Poor weight gain /
FTT 		Gastroenterology / nutrition / feeding team incl speech-language specialists
  • Low threshold for radiographic swallowing study if evidence of dysphagia
  • Gastrostomy tube placement may be required for persistent feeding issues.
Epilepsy Routine mgmt of seizures by experienced pediatric neurologistWhile seizures are generally well-controlled w/routine ASM, refractory seizures in those w/cortical dysplasia may require polytherapy.
Musculoskeletal Multidisciplinary neuromuscular clinic incl orthopedics, physical medicine, OT/PTTo focus on:
  • Maintenance of function & mobility
  • Prevention or treatment of joint & neck contractures & spine deformities
  • Activities to improve respiratory function
  • Adequate seating & wheelchair support
  • Appropriate conservation vs surgical management of spine, hips, & ankles
Respiratory Pulmonologist
  • Goals are clearance of secretions & assisted ventilation as needed to maintain oxygenation & avoid hypercapnia.
  • Aggressive treatment of respiratory infections
  • Consider positive-pressure ventilation & tracheostomy in individuals w/severe bulbar involvement & chronic aspiration & pneumonia.
Psychiatric Referral to psychologist/
psychiatrist		If concerns about mood, behavior
Cardiac By pediatric cardiologistEarly detection & treatment of myocardial dysfunction
Abnormal vision
&/or strabismus 		Standard treatment(s) per ophthalmologist

ASM = anti-seizure medication; DD = developmental delay; FTT = failure to thrive; ID = intellectual disability; OT = occupational therapist; PT = physical therapist

Developmental Delay / Intellectual Disability Management Issues

The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States (US); standard recommendations may vary significantly from country to country.

Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.

Ages 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.

All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:

  • IEP services:
    • An IEP provides specially designed instruction and related services to children who qualify.
    • IEP services will be reviewed annually to determine whether any changes are needed.
    • As required by special education law, children should be in the least restrictive environment feasible at school and included in general education as much as possible and when appropriate.
    • Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.
    • PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
    • As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.
  • A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.
  • Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
  • Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.

Communication Issues

Consider evaluation for alternative means of communication (e.g., augmentative and alternative communication [AAC]) for individuals who have expressive language difficulties. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech, but rather support optimal speech and language development.

Social/Behavioral Concerns

Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications such as medication used to treat attention-deficit/hyperactivity disorder when necessary.

Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.

Late-Onset LAMA2-MD

The care measures are similar to those described for children but adapted to age and phenotype. A multidisciplinary approach includes respiratory and orthopedic care due to the risk for progressive respiratory insufficiency and joint and spinal deformities. Cardiac surveillance is necessary due to cardiomyopathy and cardiac conduction defects. Regular physical therapy for stretching limbs, shoulder and pelvic girdle, and spine is mandatory. Anti-seizure medication is used to treat seizures.

Surveillance

Table 5.

Recommended Surveillance for Individuals with LAMA2 Muscular Dystrophy

System/ConcernEvaluationFrequency
Constitutional &
feeding 		Height, weight, nutritional status, & safety of oral intakeAt least 2x/yr in 1st 5 yrs
Neurologic Neurologic assessment for progression of weaknessAnnually or more often for acute exacerbation
EEGIf concerns for new seizure activity or progression of seizures
Respiratory Assessment by pulmonologist of pulmonary function & aspiration riskAt least annually
Neurodevelopmental Assessment of general developmental progress incl speech-language evalAt least 2x/yr in 1st 5 yrs
Cognitive/psychiatric assessment; referral to (pediatric) psychiatry if neededAnnually
Musculoskeletal Physical medicine, OT/PT assessment of strength, joint range of motion, mobility, self-help skillsAnnually
Eval of spine for scoliosis
  • At least annually
  • More often during periods of rapid growth, loss of function, or respiratory compromise
Cardiac Eval by cardiologist
  • For persons w/severe respiratory insufficiency: at least annually
  • For those w/palpitations, ↑ fatigue, or loss of consciousness w/o clear neurologic origin
  • If no cardiac symptoms: at age 5 yrs, 10 yrs, & then every 2 yrs
Ophthalmologic By ophthalmologistAnnually
Family/Community
  • Ensure appropriate social work involvement to connect families w/local resources, respite, & support.
  • Care coordination to manage multiple subspecialty appointments, equipment, medications, & supplies
According to individual needs

OT = occupational therapy; PT = physical therapy

Agents/Circumstances to Avoid

Avoid the following:

  • Succinylcholine in induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities
  • Statins, cholesterol-lowering medications, because of the risk of muscle damage

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

New treatment strategies are being investigated for LAMA2-MD [Yurchenco et al 2018, Nguyen et al 2019].

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

LAMA2 muscular dystrophy (LAMA2-MD) is an autosomal recessive disorder caused by biallelic LAMA2 pathogenic variants.

Risk to Family Members

Parents of a proband

  • In most families, both parents of an affected child are carriers of one LAMA2 pathogenic variant.
  • Accurate recurrence risk counseling relies on carrier testing of both parents to determine if each is heterozygous for a LAMA2 pathogenic variant. If the variant is detected in only one parent (and parental identity testing has confirmed biological maternity and paternity) and the child:
    • Appears to have homozygous LAMA2 pathogenic variants, possible explanations include: a large deletion on one allele (if not previously tested for); and uniparental (segmental) isodisomy for chromosome 6 [Andrade et al 2014];
    • Has compound heterozygous LAMA2 pathogenic variants, the child may have one inherited variant and one de novo variant [Zhou et al 2018].
  • Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Sibs of a proband

  • If both parents are known to be heterozygous for a LAMA2 pathogenic variant each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
  • If only one parent is heterozygous for a LAMA2 pathogenic variant, each sib of an affected individual has at conception a 50% chance of being an asymptomatic carrier and a 50% chance of being unaffected and not a carrier (the risk to the sibs of being affected with LAMA2-MD is not increased over that of the general population).
  • Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Offspring of a proband. The offspring of an individual with LAMA2-MD are obligate heterozygotes (carriers) for a LAMA2 pathogenic variant.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of a LAMA2 pathogenic variant.

Carrier Detection

Carrier testing for at-risk relatives requires prior identification of the LAMA2 pathogenic variants in the family.

Related Genetic Counseling Issues

Family planning

  • The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.

Prenatal Testing and Preimplantation Genetic Testing

Once the LAMA2 pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Association Francaise contre les Myopathies (AFM)
    France
    Phone: +33 01 69 47 28 28
    Email: dmc@afm.genethon.fr
  • Cure CMD
    Phone: 562-444-5656
  • European Neuromuscular Centre (ENMC)
    Netherlands
    Phone: 31 35 5480481
    Email: enmc@enmc.org
  • Japan Muscular Dystrophy Association
    Japan
    Phone: 03-6907-3521
  • Muscular Dystrophy Association (MDA) - USA
    Phone: 833-275-6321
    Email: ResourceCenter@mdausa.org
  • Muscular Dystrophy UK
    United Kingdom
    Phone: 0800 652 6352
  • Congenital Muscle Disease International Registry (CMDIR)
    The CMDIR is a global partnership of patient advocacy organizations, researchers, and clinicians, all working toward the same goal: to find treatments for congenital muscle disease.
    CMDIR/Cure CMD

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

LAMA2 Muscular Dystrophy: Genes and Databases

GeneChromosome LocusProteinLocus-Specific DatabasesHGMDClinVar
LAMA2 6q22​.33 Laminin subunit alpha-2 LAMA2 homepage - Leiden Muscular Dystrophy pages LAMA2 LAMA2

Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.

Table B.

OMIM Entries for LAMA2 Muscular Dystrophy (View All in OMIM)

156225LAMININ, ALPHA-2; LAMA2
253900MUSCULAR DYSTROPHY, CONGENITAL, PRODUCING ARTHROGRYPOSIS
254100MUSCULAR DYSTROPHY, CONGENITAL, WITH RAPID PROGRESSION; MDRP
607855MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A

Molecular Pathogenesis

LAMA2-MD is caused by defects in the α2 chain (encoded by LAMA2) of laminin-211 (previously known as laminin type 2 or merosin) and also laminin-221 (laminin type 4 or s-merosin).

Laminins are a group of heterotrimeric glycoproteins, composed of a heavy α chain and two light chains, β and γ, each encoded by separate genes. To date, five α chains (designated α1 to α5), three β chains (β1 to β3), and three γ chains (γ1 to γ3) have been identified, which combine to form 15 laminin isoforms [Aumailley et al 2005], each with tissue and/or developmental stage-specific expression [Suzuki et al 2005]. The biologic functions of laminins are diverse and include cell-cell recognition, growth, differentiation, cell shape, and migration [Suzuki et al 2005].

The link between the sarcolemma of muscle fibers and the extracellular matrix is established by laminin-211, being a major component of the extrasynaptic skeletal muscle basement membrane [Durbeej 2015]. Laminin-211 binds the glycosylated residues of α-dystroglycan and also self-assembles (polymerizes) into networks through its N-terminal domain [Yurchenco 2015]. This supramolecular network connects to collagen IV and to perlecan (heparan sulfate proteoglycan) through nidogen cross-linking [Jones et al 2000]. Laminin-211 expression is not limited to skeletal muscle but has also been detected in a variety of other tissues, most importantly peripheral nerve (Schwann cells) and brain [Yurchenco 2015, Yurchenco et al 2018].

Mechanism of disease causation. Biallelic pathogenic loss-of-function variants in LAMA2 are associated with complete deficiency of laminin-α2, and give rise to the severe end of the LAMA2-MD spectrum with congenital or very early onset.

Partial laminin-211 deficiency, caused by missense or in-frame variants in at least one of the mutated disease alleles, is associated with later onset and a milder phenotype.

LAMA2-specific laboratory considerations. Most of the pathogenic variants reported in LAMA2 are single-nucleotide variants or small deletions or duplications dispersed along the gene. However, copy number variants should also be considered, such as deletions involving exon 56 or exon 4 – common pathogenic variants in specific populations (see Table 6).

Table 6.

Notable LAMA2 Pathogenic Variants

Reference SequencesDNA Nucleotide ChangePredicted Protein ChangeComment [Reference]
NM_000426​.3
NP_000417​.2 		c.397-4337_639+877del 1p.(?)Common pathogenic deletion in Chinese Han [Xiong et al 2015, Ge et al 2019]
c.1580G>Ap.Cys527TyrPartial laminin α2 deficiency caused by disruption of a conserved cysteine residue [Tezak et al 2003]
c.1854_1861dupp.Leu621HisfsTer7Common pathogenic variant [Allamand & Guicheney 2002]
c.2049_2050delAGp.Arg683SerfsTer21Common pathogenic variant [Guicheney et al 1998, Hayashi et al 2001]
c.2461A>Cp.Thr821ProLate-onset variant [Oliveira et al 2018]
c.2584T>Cp.Cys862ArgPartial laminin α2 deficiency caused by disruption of a conserved cysteine residue [Tezak et al 2003]
c.2901C>Ap.Cys976TerItalian founder variant [Guicheney et al 1998, Di Blasi et al 2005]
c.2986T>Cp.Cys996ArgPartial laminin α2 deficiency caused by disruption of a conserved cysteine residue [Tezak et al 2003]
c.3085C>Tp.Arg1029TerCommon pathogenic variant [Allamand & Guicheney 2002]
c.3924+2T>Cp.Leu1246_Glu1308delMiddle East or Sudan; founder variant [Di Blasi et al 2011]
c.3976C>Tp.Arg1326TerCommon pathogenic variant [Allamand & Guicheney 2002]
c.7750-1713_78899-2153del 2
(5-kb deletion)		p.Ala2584HisfsTer8Common pathogenic deletion [Oliveira et al 2008, Oliveira et al 2014]
c.7881T>Gp.His2627GlnFound in large Kenyan family of Asian descent [Geranmayeh et al 2010]
c.8556_8558delp.Ile2852delPartial laminin α2 deficiency [Oliveira et al 2018]

Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.

GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen​.hgvs.org). See Quick Reference for an explanation of nomenclature.

1.

Deletion of exon 3

2.

Deletion of exon 56

References

Published Guidelines / Consensus Statements

  • Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, Béroud C, Bertini E, Bushby K,Cohn D, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R. Consensus statement on standard of care for congenital muscular dystrophies. Available online. 2010. Accessed 9-27-22.

Literature Cited

  • Abdel Aleem A, Elsaid MF, Chalhoub N, Chakroun A, Mohamed KAS, AlShami R, Kuzu O, Mohamed RB, Ibrahim K, AlMudheki N, Osman O, Ross ME. ELalamy O. Clinical and genomic characteristics of LAMA2 related congenital muscular dystrophy in a patients' cohort from Qatar. A population specific founder variant. Neuromuscul Disord. 2020;30:457–71. [PubMed: 32444167]
  • Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). Eur J Hum Genet. 2002;10:91–4. [PubMed: 11938437]
  • Andrade RC, Nevado J, de Faria Domingues de Lima MA, Saad T, Moraes L, Chimelli L, Lapunzina P, Vargas FR. Segmental uniparental isodisomy of chromosome 6 causing transient diabetes mellitus and merosin-deficient congenital muscular dystrophy. Am J Med Genet A. 2014;164A:2908–13. [PubMed: 25124546]
  • Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD. A simplified laminin nomenclature. Matrix Biol. 2005;24:326–32. [PubMed: 15979864]
  • Bentley G, Haddad F, Bull TM, Seingry D. The treatment of scoliosis in muscular dystrophy using modified Luque and Harrington-Luque instrumentation. J Bone Joint Surg Br. 2001;83:22–8. [PubMed: 11245532]
  • Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, Muntoni F, Sewry C, Béroud C, Mathews KD, Moore SA, Bellini J, Rutkowski A, North KN., Members of International Standard of Care Committee for Congenital Muscular Dystrophies. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord. 2014;24:289–311. [PMC free article: PMC5258110] [PubMed: 24581957]
  • Carboni N, Marrosu G, Porcu M, Mateddu A, Solla E, Cocco E, Maioli MA, Oppo V, Piras R, Marrosu MG. Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the laminin-α2-chain gene: a chance association or a novel phenotype? Muscle Nerve. 2011;44:826–8. [PubMed: 22006699]
  • Chan SH, Foley AR, Phadke R, Mathew AA, Pitt M, Sewry C, Muntoni F. Limb girdle muscular dystrophy due to LAMA2 mutations: diagnostic difficulties due to associated peripheral neuropathy. Neuromuscul Disord. 2014;24:677–83. [PubMed: 24957499]
  • Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. 2000;10:1–9. [PubMed: 10677857]
  • Di Blasi C, Bellafiore E, Salih MA, Manzini MC, Moore SA, Seidahmed MZ, Mukhtar MM, Karrar ZA, Walsh CA, Campbell KP, Mantegazza R, Morandi L, Mora M. Variable disease severity in Saudi Arabian and Sudanese families with c.3924 + 2 T > C mutation of LAMA2. BMC Res Notes. 2011;4:534. [PMC free article: PMC3278494] [PubMed: 22166137]
  • Di Blasi C, Piga D, Brioschi P, Moroni I, Pini A, Ruggieri A, Zanotti S, Uziel G, Jarre L, Della Giustina E, Scuderi C, Jonsrud C, Mantegazza R, Morandi L, Mora M. LAMA2 gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect. Arch Neurol. 2005;62:1582–6. [PubMed: 16216942]
  • Di Muzio A, De Angelis MV, Di Fulvio P, Ratti A, Pizzuti A, Stuppia L, Gambi D, Uncini A. Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve. 2003;27:500–6. [PubMed: 12661054]
  • Durbeej M. Laminin-α2 chain-deficient congenital muscular dystrophy: pathophysiology and development of treatment. Curr Top Membr. 2015;76:31–60. [PubMed: 26610911]
  • Endo T. Glycobiology of α-dystroglycan and muscular dystrophy. J Biochem. 2015;157:1–12. [PubMed: 25381372]
  • Ge L, Zhang C, Wang Z, Chan SHS, Zhu W, Han C, Zhang X, Zheng H, Wu L, Jin B, Shan J, Mao B, Zhong J, Peng X, Cheng Y, Hu J, Sun Y, Lu J, Hua Y, Zhu S, Wei C, Wang S, Jiao H, Yang H, Fu X, Fan Y, Chang X, Wang S, Bao X, Zhang Y, Wang J, Wu Y, Jiang Y, Yuan Y, Rutkowski A, Bönnemann CG, Wei W, Wu X, Xiong H. Congenital muscular dystrophies in China. Clin Genet. 2019;96:207–15. [PubMed: 31066047]
  • Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, Abbs S, Brueton L, Childs A-M, Jungbluth H, De Goede CG, Lynch B, Lin J-P, Chow G, de Sousa C, O'Mahony O, Majumdar A, Straub V, Bushby K, Muntoni F. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord. 2010;20:241–50. [PubMed: 20207543]
  • Graziano A, Bianco F, D'Amico A, Moroni I, Messina S, Bruno C, Pegoraro E, Mora M, Astrea G, Magri F, Comi GP, Berardinelli A, Moggio M, Morandi L, Pini A, Petillo R, Tasca G, Monforte M, Minetti C, Mongini T, Ricci E, Gorni K, Battini R, Villanova M, Politano L, Gualandi F, Ferlini A, Muntoni F, Santorelli FM, Bertini E, Pane M, Mercuri E. Prevalence of congenital muscular dystrophy in Italy: a population study. Neurology. 2015;84:904–11. [PMC free article: PMC4351663] [PubMed: 25653289]
  • Guicheney P, Vignier N, Zhang X, He Y, Cruaud C, Frey V, Helbling-Leclerc A, Richard P, Estournet B, Merlini L, Topaloglu H, Mora M, Harpey JP, Haenggeli CA, Barois A, Hainque B, Schwartz K, Tomé FM, Fardeau M, Tryggvason K. PCR based mutation screening of the laminin alpha2 chain gene (LAMA2): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy. J Med Genet. 1998;35:211–7. [PMC free article: PMC1051244] [PubMed: 9541105]
  • Harris E, McEntagart M, Topf A, Lochmüller H, Bushby K, Sewry C, Straub V. Clinical and neuroimaging findings in two brothers with limb girdle muscular dystrophy due to LAMA2 mutations. Neuromuscul Disord. 2017;27:170–4. [PubMed: 27932089]
  • Hayashi YK, Tezak Z, Momoi T, Nonaka I, Garcia CA, Hoffman EP, Arahata K. Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord. 2001;11:350–9. [PubMed: 11369186]
  • He Y, Jones KJ, Vignier N, Morgan G, Chevallay M, Barois A, Estournet-Mathiaud B, Hori H, Mizuta T, Tomé FM, North KN, Guicheney P. Congenital muscular dystrophy with primary partial laminin alpha2 chain deficiency: molecular study. Neurology. 2001;57:1319–22. [PubMed: 11591858]
  • Jones JC, Dehart GW, Gonzales M, Goldfinger LE. Laminins: an overview. Microsc Res Tech. 2000;51:211–3. [PubMed: 11054871]
  • Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, North KN. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet. 2001;38:649–57. [PMC free article: PMC1734735] [PubMed: 11584042]
  • Leite CC, Reed UC, Otaduy MC, Lacerda MT, Costa MO, Ferreira LG, Carvalho MS, Resende MB, Marie SK, Cerri GG. Congenital muscular dystrophy with merosin deficiency: 1H MR spectroscopy and diffusion-weighted MR imaging. Radiology. 2005;235:190–6. [PubMed: 15703311]
  • Marques J, Duarte ST, Costa S, Jacinto S, Oliveira J, Oliveira ME, Santos R, Bronze-da-Rocha E, Silvestre AR, Calado E, Evangelista T. Atypical phenotype in two patients with LAMA2 mutations. Neuromuscul Disord. 2014;24:419–24. [PubMed: 24534542]
  • Menezes MJ, McClenahan FK, Leiton CV, Aranmolate A, Shan X, Colognato H. The extracellular matrix protein laminin α2 regulates the maturation and function of the blood-brain barrier. J Neurosci. 2014;34:15260–80. [PMC free article: PMC6608454] [PubMed: 25392494]
  • Mercuri E, Gruter-Andrew J, Philpot J, Sewry C, Counsell S, Henderson S, Jensen A, Naom I, Bydder G, Dubowitz V, Muntoni F. Cognitive abilities in children with congenital muscular dystrophy: correlation with brain MRI and merosin status. Neuromuscul Disord. 1999;9:383–7. [PubMed: 10545041]
  • Messina S, Bruno C, Moroni I, Pegoraro E, D'Amico A, Biancheri R, Berardinelli A, Boffi P, Cassandrini D, Farina L, Minetti C, Moggio M, Mongini T, Mottarelli E, Pane M, Pantaleoni C, Pichiecchio A, Pini A, Ricci E, Saredi S, Sframeli M, Tortorella G, Toscano A, Trevisan CP, Uggetti C, Vasco G, Comi GP, Santorelli FM, Bertini E, Mercuri E. Congenital muscular dystrophies with cognitive impairment. A population study. Neurology. 2010;75:898–903. [PubMed: 20820001]
  • Natera-de Benito D, Muchart J, Itzep D, Ortez C, González-Quereda L, Gallano P, Ramirez A, Aparicio J, Domínguez-Carral J, Carrera-García L, Expósito-Escudero J, Pardo Cardozo N, Cuadras D, Codina A, Jou C, Jimenez-Mallebrera C, Palau F, Colomer J, Arzimanoglou A, Nascimento A, San Antonio-Arce V. Epilepsy in LAMA2-related muscular dystrophy: an electro-clinico-radiological characterization. Epilepsia. 2020;2020;61:971–83. [PubMed: 32266982]
  • Nelson I, Stojkovic T, Allamand V, Leturcq F, Bécane HM, Babuty D, Toutain A, Béroud C, Richard P, Romero NB, Eymard B, Ben Yaou R, Bonne G. Laminin α2 deficiency-related muscular dystrophy mimicking emery-dreifuss and collagen vi related diseases. J Neuromuscul Dis. 2015;2:229–40. [PMC free article: PMC5240538] [PubMed: 27858741]
  • Nguyen Q, Lim KRQ, Yokota T. Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy. Appl Clin Genet. 2019;12:113–30. [PMC free article: PMC6618038] [PubMed: 31308722]
  • O'Grady GL, Lek M, Lamande SR, Waddell L, Oates EC, Punetha J, Ghaoui R, Sandaradura SA, Best H, Kaur S, Davis M, Laing NG, Muntoni F, Hoffman E, MacArthur DG, Clarke NF, Cooper S, North K. Diagnosis and etiology of congenital muscular dystrophy: we are halfway there. Ann Neurol. 2016;80:101–11. [PubMed: 27159402]
  • Oliveira J, Gonçalves A, Oliveira ME, Fineza I, Pavanello RC, Vainzof M, Bronze-da-Rocha E, Santos R, Sousa M. Reviewing large LAMA2 deletions and duplications in congenital muscular dystrophy patients. J Neuromuscul Dis. 2014;1:169–79. [PubMed: 27858771]
  • Oliveira J, Gruber A, Cardoso M, Taipa R, Fineza I, Gonçalves A, Laner A, Winder TL, Schroeder J, Rath J, Oliveira ME, Vieira E, Sousa AP, Vieira JP, Lourenço T, Almendra L, Negrão L, Santos M, Melo-Pires M, Coelho T, den Dunnen JT, Santos R, Sousa M. LAMA2 gene mutation update: toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat. 2018;39:1314–37. [PubMed: 30055037]
  • Oliveira J, Santos R, Soares-Silva I, Jorge P, Vieira E, Oliveira ME, Moreira A, Coelho T, Ferreira JC, Fonseca MJ, Barbosa C, Prats J, Aríztegui ML, Martins ML, Moreno T, Heinimann K, Barbot C, Pascual-Pascual SI, Cabral A, Fineza I, Santos M, Bronze-da-Rocha E. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. Clin Genet. 2008;74:502–12. [PubMed: 18700894]
  • Pegoraro E, Marks H, Garcia CA, Crawford T, Mancias P, Connolly AM, Fanin M, Martinello F, Trevisan CP, Angelini C, Stella A, Scavina M, Munk RL, Servidei S, Bönnemann CC, Bertorini T, Acsadi G, Thompson CE, Gagnon D, Hoganson G, Carver V, Zimmerman RA, Hoffman EP. Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology. 1998;51:101–10. [PubMed: 9674786]
  • Philpot J, Bagnall A, King C, Dubowitz V, Muntoni F. Feeding problems in merosin deficient congenital muscular dystrophy. Arch Dis Child. 1999a;80:542–7. [PMC free article: PMC1717951] [PubMed: 10332004]
  • Philpot J, Cowan F, Pennock J, Sewry C, Dubowitz V, Bydder G, Muntoni F. Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging. Neuromuscul Disord. 1999b;9:81–5. [PubMed: 10220862]
  • Pini A, Merlini L, Tomé FM, Chevallay M, Gobbi G. Merosin-negative congenital muscular dystrophy, occipital epilepsy with periodic spasms and focal cortical dysplasia. Report of three Italian cases in two families. Brain Dev. 1996;18:316–22. [PubMed: 8879653]
  • Quijano-Roy S, Renault F, Romero N, Guicheney P, Fardeau M, Estournet B. EMG and nerve conduction studies in children with congenital muscular dystrophy. Muscle Nerve. 2004;29:292–9. [PubMed: 14755496]
  • Rajakulendran S, Parton M, Holton JL, Hanna MG. Clinical and pathological heterogeneity in late-onset partial merosin deficiency. Muscle Nerve. 2011;44:590–3. [PubMed: 21922472]
  • Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24. [PMC free article: PMC4544753] [PubMed: 25741868]
  • Saredi S, Gibertini S, Matalonga L, Farina L, Ardissone A, Moroni I, Mora M. Exome sequencing detects compound heterozygous nonsense LAMA2 mutations in two siblings with atypical phenotype and nearly normal brain MRI. Neuromuscul Disord. 2019;29:376–80. [PubMed: 31040037]
  • Sframeli M, Sarkozy A, Bertoli M, Astrea G, Hudson J, Scoto M, Mein R, Yau M, Phadke R, Feng L, Sewry C, Fen ANS, Longman C, McCullagh G, Straub V, Robb S, Manzur A, Bushby K, Muntoni F. Congenital muscular dystrophies in the UK population: clinical and molecular spectrum of a large cohort diagnosed over a 12-year period. Neuromuscul Disord. 2017;27:793–803. [PubMed: 28688748]
  • Straub V, Murphy A, Udd B, et al. 229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul Disord. 2018;28:702–10. [PubMed: 30055862]
  • Sunada Y, Edgar TS, Lotz BP, Rust RS, Campbell KP. Merosin-negative congenital muscular dystrophy associated with extensive brain abnormalities. Neurology. 1995;45:2084–9. [PubMed: 7501163]
  • Suzuki N, Yokoyama F, Nomizu M. Functional sites in the laminin alpha chains. Connect Tissue Res. 2005;46:142–52. [PubMed: 16147852]
  • Tezak Z, Prandini P, Boscaro M, Marin A, Devaney J, Marino M, Fanin M, Trevisan CP, Park J, Tyson W, Finkel R, Garcia C, Angelini C, Hoffman EP, Pegoraro E. Clinical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (LAMA2) deficiency. Hum Mutat. 2003;21:103–11. [PubMed: 12552556]
  • Tordjman M, Dabaj I, Laforet P, Felter A, Ferreiro A, Biyoukar M, Law-Ye B, Zanoteli E, Castiglioni C, Rendu J, Beroud C, Chamouni A, Richard P, Mompoint D, Quijano-Roy S, Carlier RY. Muscular MRI-based algorithm to differentiate inherited myopathies presenting with spinal rigidity. Eur Radiol. 2018;28:5293–303. [PubMed: 29802573]
  • Vigliano P, Dassi P, Di Blasi C, Mora M, Jarre L. LAMA2 stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. Eur J Paediatr Neurol. 2009;13:72–6. [PubMed: 18406646]
  • Wallgren-Pettersson C, Bushby K, Mellies U, Simonds A. 117th ENMC workshop: ventilatory support in congenital neuromuscular disorders -- congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, the Netherlands. Neuromuscul Disord. 2004;14:56–69. [PubMed: 14659414]
  • Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, Béroud C, Bertini E, Bushby K, Cohn RD, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010;25:1559–81. [PMC free article: PMC5207780] [PubMed: 21078917]
  • Xiong H, Tan D, Wang S, Song S, Yang H, Gao K, Liu A, Jiao H, Mao B, Ding J, Chang X, Wang J, Wu Y, Yuan Y, Jiang Y, Zhang F, Wu H, Wu X. Genotype/phenotype analysis in Chinese laminin-α2 deficient congenital muscular dystrophy patients. Clin Genet. 2015;87:233–43. [PubMed: 24611677]
  • Yurchenco PD. Integrating activities of laminins that drive basement membrane assembly and function. Curr Top Membr. 2015;76:1–30. [PubMed: 26610910]
  • Yurchenco PD, McKee KK, Reinhard JR, Rüegg MA. Laminin-deficient muscular dystrophy: molecular pathogenesis and structural repair strategies. Matrix Biol. 2018;71-2:174–87. [PMC free article: PMC5971131] [PubMed: 29191403]
  • Zhou J, Tan J, Ma D, Zhang J, Cheng J, Luo C, Liu G, Wang Y, Xu Z. Identification of two novel LAMA2 mutations in a Chinese patient with congenital muscular dystrophy. Front Genet. 2018;9:43. [PMC free article: PMC5816747] [PubMed: 29487616]

Chapter Notes

Author Notes

JO maintains the LAMA2 locus-specific database (in collaboration with Prof Johan T den Dunnen, Leiden University Medical Center) with the aim to further expand the mutational spectrum and genotype-phenotype correlations in LAMA2 muscular dystrophies.

Acknowledgments

The authors would like to thank the extensive list of collaborators who over the years contributed to improve the current scientific knowledge about LAMA2 muscular dystrophies.

Author History

Teresa Coelho, MD, PhD (2020-present)
Jorge Oliveira, MSc, PhD (2020-present)
João Parente Freixo, MD (2020-present)
Susana Quijano-Roy, MD, PhD; Hôpital Raymond Poincaré (2012-2020)
Anne Rutkowski, MD; Kaiser Permanente Southern California (2012-2020)
Manuela Santos, MD (2020-present)
Susan E Sparks, MD, PhD; Sanofi Genzyme (2012-2020)

Revision History

  • 17 September 2020 (bp) Comprehensive update posted live
  • 7 June 2012 (me) Review posted live
  • 16 March 2010 (ss) Initial submission
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK97333PMID: 22675738
GeneReviews by Title